Stocks · News reference
Polaryx Therapeutics Says It Remains On Track To Initiate Phase 2 SOTERIA Basket Trial Of PLX-200 In Four Pediatric Lysosomal Storage Disorders In Q4 2026
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 25, 2026, 12:32 PM
- Checked
- Aug 25, 2026, 12:32 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
Wall Street analysts changed outlook on top names. Check analyst ratings page for all changes. See what analysts think of MTN stock.
Read original at benzingaRaymond James Initiates Coverage On Polaryx Therapeutics with Strong Buy Rating, Announces Price Target of $6
Raymond James analyst Tiago Fauth initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Strong Buy rating and announces Price Target of $6.
Read original at benzinga